Cargando…

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect

Colorectal cancer (CRC), as one of the most prevalent types of cancer worldwide, is still a leading cause of cancer related mortality. There is an urgent need for more efficient therapies in metastatic disease. Immunotherapy, a rapidly expanding field of oncology, is designed to boost the body'...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, Julie, Smits, Evelien, Lardon, Filip, Pauwels, Patrick, Deschoolmeester, Vanessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641952/
https://www.ncbi.nlm.nih.gov/pubmed/26605342
http://dx.doi.org/10.1155/2015/158038
_version_ 1782400272800153600
author Jacobs, Julie
Smits, Evelien
Lardon, Filip
Pauwels, Patrick
Deschoolmeester, Vanessa
author_facet Jacobs, Julie
Smits, Evelien
Lardon, Filip
Pauwels, Patrick
Deschoolmeester, Vanessa
author_sort Jacobs, Julie
collection PubMed
description Colorectal cancer (CRC), as one of the most prevalent types of cancer worldwide, is still a leading cause of cancer related mortality. There is an urgent need for more efficient therapies in metastatic disease. Immunotherapy, a rapidly expanding field of oncology, is designed to boost the body's natural defenses to fight cancer. Of the many approaches currently under study to improve antitumor immune responses, immune checkpoint inhibition has thus far been proven to be the most effective. This review will outline the treatments that take advantage of our growing understanding of the role of the immune system in cancer, with a particular emphasis on immune checkpoint molecules, involved in CRC pathogenesis.
format Online
Article
Text
id pubmed-4641952
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-46419522015-11-24 Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect Jacobs, Julie Smits, Evelien Lardon, Filip Pauwels, Patrick Deschoolmeester, Vanessa J Immunol Res Review Article Colorectal cancer (CRC), as one of the most prevalent types of cancer worldwide, is still a leading cause of cancer related mortality. There is an urgent need for more efficient therapies in metastatic disease. Immunotherapy, a rapidly expanding field of oncology, is designed to boost the body's natural defenses to fight cancer. Of the many approaches currently under study to improve antitumor immune responses, immune checkpoint inhibition has thus far been proven to be the most effective. This review will outline the treatments that take advantage of our growing understanding of the role of the immune system in cancer, with a particular emphasis on immune checkpoint molecules, involved in CRC pathogenesis. Hindawi Publishing Corporation 2015 2015-10-29 /pmc/articles/PMC4641952/ /pubmed/26605342 http://dx.doi.org/10.1155/2015/158038 Text en Copyright © 2015 Julie Jacobs et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Jacobs, Julie
Smits, Evelien
Lardon, Filip
Pauwels, Patrick
Deschoolmeester, Vanessa
Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
title Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
title_full Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
title_fullStr Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
title_full_unstemmed Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
title_short Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
title_sort immune checkpoint modulation in colorectal cancer: what's new and what to expect
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641952/
https://www.ncbi.nlm.nih.gov/pubmed/26605342
http://dx.doi.org/10.1155/2015/158038
work_keys_str_mv AT jacobsjulie immunecheckpointmodulationincolorectalcancerwhatsnewandwhattoexpect
AT smitsevelien immunecheckpointmodulationincolorectalcancerwhatsnewandwhattoexpect
AT lardonfilip immunecheckpointmodulationincolorectalcancerwhatsnewandwhattoexpect
AT pauwelspatrick immunecheckpointmodulationincolorectalcancerwhatsnewandwhattoexpect
AT deschoolmeestervanessa immunecheckpointmodulationincolorectalcancerwhatsnewandwhattoexpect